Australia says CSL unit Seqirus to discontinue Benpen injections from November
27/05/2026 08:15
Australia says CSL unit Seqirus to discontinue Benpen injections from November May 27 (Reuters) - Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's CSL.AX unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progressively due to commercial reasons.
CSL's vaccine arm notified the regulator that the discontinuation will start with the 600 milligrams (mg) strength from 30 November 2026.
(Reporting by Shivangi Lahiri in Bengaluru)
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX